Dr. Marashi discusses about the recent trends in the fixed duration treatment regimens for CLL and use of combination therapy.
Dr. Mahmoud Marashi, UAE
Dr. Mahmoud Marashi, Consultant Haematologist, Mediclinic City Hospital, United Arab Emirates, lectures on the Review on Fixed Duration Regimen in CLL Management and talks about the following points
• Recent developments in the fixed duration treatment regimens for CLL and use of combination therapy
• GLOW trial data and importance of ibrutinib + venetoclax demonstrated in previously untreated CLL as compared to chlorambucil + obinutuzumab.
• CAPTIVATE trial data and first line ibrutinib + venetoclax in patients with CLL.
• AVO study where patients were treated initially with obinutuzumab and then shifted combination of acalabrutinib and venetoclax
• Key points of CLL 13 study
Explore more videos
Review on Time to Progression Regimen in CLL Management
Dr. George Follows, UK
Translating data into practice
Dr. Ihab El-Hemaidi, KSA
The CLL Management in Clinic
Dr. Hani Osman, UAE